elimusertib (BAY 1895344) / Bayer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elimusertib (BAY 1895344) / Bayer
NCT03188965 / 2016-004484-39: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Completed
2
229
Europe, Canada, Japan, US, RoW
Elimusertib (BAY1895344)
Bayer
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
12/22
09/23
PEPN2112, NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Active, not recruiting
1/2
23
Canada, US
Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344
National Cancer Institute (NCI)
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
12/24
12/24

Download Options